100% success rate across programs to date*
Anti-drug and anti-idiotypic antibody discovery
Anti-idiotypic and anti-drug antibody discovery designed for precision, delivering reproducible results across diverse formats and assay needs.
The critical link for research
MindWalk delivers what few can claim—a 100% success rate in anti-idiotypic antibody discovery to date.*
Our discovery programs move with speed and rigor, combining scientific expertise with highly trackable, regulatory-facing workflows designed for IND-enabling discovery. With validated assays and reproducible data packages, MindWalk provides the precision and reliability you need as candidates move into downstream development.
* “Success” refers to the generation of anti-idiotypic antibodies meeting predefined analytical criteria across Anti-ID discovery programs. It does not refer to clinical, regulatory, or therapeutic outcomes. Results may vary.
Performance driven
High-affinity and exquisite specificity
Scalable workflows with versatile formats
Customizable solutions
35+ years of experience High client retention
Clear obstacles and reduce bottlenecks
LensAI™ analysis for affinity, specificity, and selectivity
Fully customizable discovery built to support strong outcomes
A global leader:
Delivering anti-idiotypic antibody discovery and research tool innovation at scale
1,100+ programs completed
Average timeline:
B cell discovery: From immunization to delivery
<12 weeks*
*Timelines may vary depending on program complexity.
Where our research makes a broad impact
Oncology + Infectious Disease + Neurodegeneration + Metabolic Disease + Rare Disease + Inflammation
Anti-idiotype discovery across complex targets
Antibody discovery + development
Versatile Applications: anti-drug & anti-idiotypic and other research tools (Western Blot, IHC, Flow Cytometry and other applications)
Target
- Target Analysis: Experience-based Antigen Design
- Tool Generation: Custom Antigen Production, Assay Development
Discovery
- Immunization: Standard, Rapid, Custom
- Hit Generation & Candidate Selection: B cell Discovery, Hybridoma Discovery
Lead
- Lead Characterization: Target Interaction Analysis
- LensAI™ analysis: binding affinity optimization, target specificity and selectivity
- Target- and Application-specific Screening
- Protein Production: Recombinant Protein Expression in CHO, HEK293, E.coli
Stable Production Cell Line
Functional Selection
- Epitope Mapping
- Affinity
- Specificity
- Competing/Non-competing
- Pairing Identification
- Application-relevant Screening
Species Diversity
+ Rabbit
+ Rodent
Advanced Technology
+ B cell Select® Antibody Discovery
+ Hybridoma
Format Options
- Full-length IgG
- Custom Formats
See how B cell Select®, hybridoma, and yeast display discovery work, and where LensAI™ analysis fits. Learn more
Additional discovery innovation
Veterinary medicine, diagnostics and science
Used by teams across 19 of the top 20 global pharma companies, next-generation biotechs, and leading research institutions
An extension of
your team.
#1 ranking lab*
*ROOTS 2022: Antibody Discovery Services and Platforms Market (4th Edition), 2021-2035; p.118
Tell us about your target.
A scientist, not a sales rep, replies within two business days.
Case Studies
See validated insights that redefine workflows and advance discovery
Scientific Posters
Discover how MindWalk powers smarter paths from concept to clinic.
Blogs
Explore latest ideas reshaping the future of discovery.
FAQs
-
What should I look for in an anti-idiotypic antibody discovery partner?
For anti-idiotypic antibody programs, teams should evaluate experience with PK, ADA, neutralizing antibody, and bioanalytical assay workflows. The right partner should be able to generate drug-specific and assay-relevant reagents, screen for the required binding behavior, and produce reproducible data packages for development-stage studies.
-
Can MindWalk develop anti-idiotypic antibodies for my therapeutic antibody?
Yes. MindWalk develops anti-idiotypic and anti-drug antibodies for therapeutic antibody and biologics programs, including reagents used in PK, ADA, neutralizing antibody, and bioanalytical assay workflows. Anti-ID discovery can be initiated at any stage of a client’s therapeutic antibody discovery program, including alongside therapeutic antibody discovery, with rapid timelines to support program needs.
-
What types of anti-ID antibodies can MindWalk generate?
MindWalk can support anti-ID reagent needs across multiple assay strategies, including antibodies designed to recognize therapeutic antibody binding regions, drug-specific forms, or assay-relevant binding states.
-
How does MindWalk support ADA and PK assay development?
Anti-ID and anti-drug antibody reagents must be designed with the downstream assay in mind. MindWalk develops custom reagents around the therapeutic molecule, assay format, specificity requirements, and development use case to support reliable PK, ADA, neutralizing antibody, and bioanalytical workflows.